GlassScriptPhysician profile
Ashley N Mitchell
NPI 1346747839
$1,959.45
in general payments reported to CMS, 2019-2025
35 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,155 · 2022: $312 · 2023: $155 · 2024: $128 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.93 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $238.07 | 2021-2025 | Airsupra |
| Amgen INC. | $192.26 | 2021-2023 | Repatha |
| Pharmacyclics LLC, An Abbvie Company | $180.86 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $168.89 | 2021-2025 | Rybrevant, Tremfya |
| Incyte Corporation | $163.31 | 2021-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $116.61 | 2021-2023 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $94.00 | 2021-2024 | Enhertu |
| Abbvie INC. | $65.31 | 2024-2025 | |
| Astellas Pharma US INC | $60.39 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $53.20 | 2021 | |
| Genentech USA, INC. | $46.04 | 2021-2022 | |
| Tersera Therapeutics LLC | $42.06 | 2021-2023 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.92 | 2021 | |
| Celgene Corporation | $39.05 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $38.93 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $35.46 | 2021 | |
| Epizyme, INC. | $33.34 | 2021-2022 | |
| Mirati Therapeutics, INC. | $33.17 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2021-2022 | |
| Stemline Therapeutics INC. | $27.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.23 | 2021 | |
| Genzyme Corporation | $21.31 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.02 | 2024 | Voquezna |
| Rigel Pharmaceuticals, INC. | $19.56 | 2022 | |
| G1 Therapeutics, INC. | $18.49 | 2021 | |
| Sobi, INC | $17.14 | 2022 | |
| Servier Pharmaceuticals LLC | $17.12 | 2021 | |
| Secura Bio, INC. | $16.90 | 2022 | |
| Abiomed | $16.39 | 2022 | |
| Eisai INC. | $14.65 | 2021 | |
| Heron Therapeutics, INC. | $14.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.66 | 2021 | |
| Seagen INC. | $12.66 | 2021 | |
| Dova Pharmaceuticals | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.